By Stacie Prada Last year, my naturopath suggested I take deep breaths each day, and I agreed it would be good for me. I approached it like a prescription and made sure to do it. I followed guided meditations, and … Continue reading → Source:…
Regulators in the European Union are recommendeding that tolebrutinib be approved as a treatment for people with secondary progressive multiple sclerosis (SPMS) who have not experienced a relapse in the last two years. That new positive opinion was issued by the European Medicines Agency’s Committee…
Concert tickets might sound like a small thing, but for Dan and me, they’re not. Live music is one of our favorite ways to feel connected, normal, and joyful beyond the daily realities of living with Multiple Sclerosis. A couple of weeks ago, I tried…
Tweet MS treatments are expensive and it is OK if you live in a place with Social Medicine but in many parts of the World one of the features that limits access to treatments is economics. It is scandalous that some countries penalise people for…
Tweet Anti-drug antibodies can stop drugs from working and can cause infusion reactions. They are rare to common occurrances due to the target the drug, the person, the assay, the reporting levels and the route. The subcutaneous route is under the skin and can induce…
I’m learning more and more about how the realities of my disabled life affect my psyche and leave me feeling traumatized. For many reasons, I am often left alone unplanned in very vulnerable positions. For example, during the day you’ll often find me sitting at…
Tweet Yep the good news is that the EMA has approved the French Drug for progressive MS. This a Brutons Tyrosine kinase inhibitor that the FDA pushed back on. Will this arrive and make it past NICE in the UK well it has to be…
It’s the last day of MS Awareness Week with the campaign of #MSThinkAgain, which has been challenging all the assumptions that surround the condition, which just aren’t true. Every day this week, Dizzy and I have been considering the misconceptions we have encountered, and…
By Samuel Fitch There comes a point where continuing the same patterns will only lead you further away from the life you actually want to live. For me, that moment wasn’t dramatic. It was quiet, but undeniable. Between living with … Continue reading → Source:…
Ocrevus (ocrelizumab) delayed disability progression and worsening hand function among a large group of people with primary progressive multiple sclerosis (PPMS), including those who were older and had more advanced disease. The data, which come from the Phase 3 ORATORIO-HAND trial (NCT04035005), were presented by…